-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target

Benzinga·08/14/2026 13:37:38
Listen to the news
Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $55 price target.